Inconclusive - Merck's ViP Study on Vioxx and Cancer
ViP was a multicenter, randomized, double-blinded, placebo-controlled study to examine the effects of Vioxx in decreasing the risk for prostate cancer. The study was finalized in March 2003 and enrollment for the study began on June of 2003. The group consisted of 15,000 male patients at the ages of 50 and 75 years where their life expectancy exceeded the time frame of 6 years. Patients would consume 25mg of Vioxx per day where cardiovascular adverse events were monitored by an external safety monitoring board similar to that in the clinical study APPROVe. This trial was terminated on 30 September 2004 after Merck voluntarily recalled Vioxx from the market.
If you or a loved one has suffered due to a side effect of Vioxx, you can fill out this simple form for a free case review within 24 hours.
Weitz & Luxenberg is no longer accepting Vioxx cases.
see also:
VICTOR
VICTOR - Merck's Incomplete Study on Vioxx What went wrong? Learn about VICTOR the Vioxx study that was cut short
Alzheimer's Disease
Affected by Alzheimer’s Disease? Vioxx has been tested to helpWhat you should know about Alzheimer's Disease and Vioxx testing
Vioxx Clinical Trials
Want some history? See the Vioxx Clinical Trials & FDA Studies chartWhat you need to know about Vioxx - Clinical Trials & FDA Studies
